Literature DB >> 22278389

Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes.

Mona Bidier1, Carolin Zschoche, Patrick Gholam, Alexander H Enk, Eva N Hadaschik.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22278389     DOI： 10.2340/00015555-1299

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   4.437


× No keyword cloud information.
  6 in total

Review 1.  Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

Authors:  Caterina Ferreli; Giulia Gasparini; Aurora Parodi; Emanuele Cozzani; Franco Rongioletti; Laura Atzori
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

Review 2.  [Scleromyxedema].

Authors:  M Neufeld; C Sunderkötter; R K C Moritz
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

Review 3.  New insights on scleromyxedema.

Authors:  Laura Atzori; Caterina Ferreli; Franco Rongioletti
Journal:  J Scleroderma Relat Disord       Date:  2019-01-29

4.  A Case of Autoimmune Polyglandular Syndrome .ype 2 Associated with Atypical Form of Scleromyxedema.

Authors:  Oleksander Prylutskyi; Olga Prylutska; Anatoliy Degonskyi; Kseniia Tkachenko
Journal:  Ethiop J Health Sci       Date:  2016-09

5.  Scleromyxedema with subcutaneous nodules: successful treatment with thalidomide and intravenous immunoglobulin.

Authors:  M Dolenc-Voljč; V Jurčić; A Hočevar; M Tomšič
Journal:  Case Rep Dermatol       Date:  2013-11-02

6.  Scleromyxedema: a rare disorder and its treatment difficulties.

Authors:  Sandra Koleta Koronowska; Agnieszka Osmola-Mańkowska; Oliwia Jakubowicz; Ryszard Zaba
Journal:  Postepy Dermatol Alergol       Date:  2013-04-12       Impact factor: 1.837
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.